Compare LGHL & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGHL | JAGX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.9K | 1.0M |
| IPO Year | 2020 | 2014 |
| Metric | LGHL | JAGX |
|---|---|---|
| Price | $0.68 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 408.6K | ★ 673.1K |
| Earning Date | 04-30-2024 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $77.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.20 |
| 52 Week High | $9.54 | $41.53 |
| Indicator | LGHL | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 38.36 |
| Support Level | $0.58 | $0.21 |
| Resistance Level | $1.13 | $0.46 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 3.97 | 1.14 |
Lion Group Holding Ltd provides an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, and Over-The-Counter (OTC) stock options trading business. It offers these services through its all-in-one Lion Brokers Pro app and a variety of other apps available on iOS, Android, PC, and Mac platforms. The company's clients are mostly well-educated and affluent Chinese investors residing both inside and outside the PRC (excluding the United States). Its operating segments are: OTC Stock option trading, which generates maximum revenue, CFD trading, TRS trading, and Other. Geographically, the company derives maximum revenue from Hong Kong.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.